2-(1-Benzyl-4-piperidinyl)ethanamine(CAS: 86945-25-7)

The compound 2-(1-Benzyl-4-piperidinyl)ethanamine (CAS: 86945-25-7) falls under various regulatory guidelines such as the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH in the European Union, and FDA/EPA requirements for pharmaceutical and chemical substances. Compliance is essential for manufacturers and distributors to ensure proper labeling, storage, and transportation of the compound.

There are several alternatives to 2-(1-Benzyl-4-piperidinyl)ethanamine (CAS: 86945-25-7) in synthesis, such as analogous compounds like 2-(1-phenylethyl-4-piperidinyl)ethanamine and isomers like 2-(1-(2-methylbenzyl)-4-piperidinyl)ethanamine. These alternatives can be used as substitutes depending on the specific needs of the synthesis process.

The market and research trend for 2-(1-Benzyl-4-piperidinyl)ethanamine (CAS: 86945-25-7) is primarily focused on its use in pharmaceuticals due to its potential as an agonist for histamine H3 receptors. Recent studies are exploring its efficacy in treating conditions like insomnia and as a potential therapeutic for Alzheimer's disease. Market trends indicate increasing demand in the pharmaceutical industry.

Waste containing 2-(1-Benzyl-4-piperidinyl)ethanamine (CAS: 86945-25-7) should be collected in appropriate containers and handled in accordance with local and international hazardous waste disposal regulations. Proper incineration or professional waste disposal services should be utilized to ensure environmental protection. Safety precautions should be taken during handling and disposal to prevent exposure and environmental contamination.